Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 82 clinical trials
Endoscopic Ultrasound Radiofrequency Ablation for GISTs

Nowadays, for the selection of the treatment for gastrointestinal stromal tumors (GISTs), tumor size, prognosis, resectability and stage should be considered. Due to mutations in KIT and platelet-derived growth factor alpha (PDGFRA) in 90% of patients with this mesenchymal tumor, many tyrosine kinase inhibitors are used. On the other hand, …

  • 0 views
  • 28 Jul, 2022
  • 1 location
ABL001 + Dasatinib + Prednisone in BCR-ABL+ B-ALL or CML

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome …

male sterilization
dasatinib
prednisone
gilbert's syndrome
philadelphia chromosome
  • 10 views
  • 15 Feb, 2022
  • 6 locations
Leflunomide for Musculoskeletal GVHD After Allogeneic Stem Cell Transplant

Graft versus host disease (GVHD) is a well-known complication of allogeneic transplant. In GVHD, the cells of the donor attack the patient's tissues and cause damage. It can affect any organ or system of the body. In a proportion of patients, it affects the joints and muscles. This is known …

  • 0 views
  • 28 Jun, 2021
  • 1 location
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma

In chordoma cell lines and patient biopsies, the p16 (CDKN2A) tumor suppressor is consistently deleted. Thus, chordomas are an example of a tumor with universal activation of the cyclin-dependent kinases 4 and 6 (CDK4/6) pathway, and experiments with patient-derived chordoma cell lines demonstrate aberrant CDK4/6 activity downstream of p16 loss …

imatinib
metastatic chordoma
sorafenib
vasectomy
palbociclib
  • 39 views
  • 07 Jan, 2022
  • 3 locations
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population (TOKIN)

This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.

nilotinib
tyrosine
imatinib
leukemia
remission
  • 2 views
  • 25 Mar, 2022
  • 3 locations
Flumatinib Efficacy and Safety for New Diagnosed Chronic Phase Chronic Myeloid Leukemia

patients who has poor response or intolerance for TKI drugs( Imatinib, dasatinib, nilotinib). Flumatinib has been shown to be a more potent inhibitor of BCR-ABL1 tyrosine kinase than imatinib,and it aslo

Accepts healthy volunteers
  • 0 views
  • 20 Apr, 2022
  • 1 location
Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST) (METAGIST)

. Treatment of localized forms relies on adequate surgery without tumor spillage and systemic treatment with imatinib according to risk of relapse defined by localization, tumor size and mitotic count, as

  • 0 views
  • 08 Feb, 2022
  • 1 location
Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

a new therapeutic goal for chronic myeloid leukemia in chronic phase (CML-CP). In ENESTnd and DASISION trials, both nilotinib and dasatinib achieved DMR more effectively than imatinib. In the

  • 0 views
  • 15 Feb, 2021
  • 1 location
International Chronic Myeloid Leukemia Pediatric Study (ICMLPed)

The purpose of the study is to describe and characterize CML in a large pediatric cohort of patients.

leukemia
  • 135 views
  • 07 Apr, 2022
  • 15 locations
Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib (CML0609)

The GIMEMA CML Working Party promotes an observational (retrospective and perspective) study of Imatinib-resistant or intolerant CML patients treated with Nilotinib in Italy. Enrollment will

nilotinib
leukemia
imatinib
dasatinib
  • 12 views
  • 25 Mar, 2022
  • 31 locations